PURPOSE: To analyze rate, risk factors, and costs associated with 30-day readmission after ovarian cancer surgery. PATIENTS AND METHODS: The SEER-Medicare linked database (1992 to 2010) was used to evaluate readmission rates within 30 days of index surgery in patients with stage IIIC/IV ovarian, primary peritoneal, or fallopian tube cancer. Multivariable logistic regression was used to identify factors associated with readmission. RESULTS: Of 5,152 eligible patients, 1,003 (19.5%) were readmitted within 30 days of discharge. Mean patient age was 75 years. Diagnoses associated with readmission included infection (34.7%), dehydration (34.3%), ileus/obstruction (26.2%), metabolic/electrolyte derangements (23.1%), and anemia (12.3%). In multivariable analysis, year of discharge was significantly associated with 30-day readmission (1996 to 2000: odds ratio [OR], 1.32; 95% CI, 1.01 to 1.71; 2001 to 2005: OR, 1.58; 95% CI, 1.24 to 2.0; 2006 to 2010: OR, 1.73; 95% CI, 1.35 to 2.21; referent years 1992 to 1995), as were length of index hospital stay more than 8 days (OR, 1.39; 95% CI, 1.18 to 1.64) and discharge to a skilled nursing facility (OR, 1.3; 95% CI, 1.04 to 1.63). Patients readmitted within 30 days had a significantly greater 1-year mortality rate compared with patients not readmitted (41.1% v 25.1%, respectively; P < .001). The median cost of readmission hospital stay was $9,220 in year 2010 dollars, with a total cost of $9.3 million over the study period. CONCLUSION: Early readmission after surgery for ovarian cancer is common. There is a significant association between 30-day readmission and 1-year mortality. These findings may catalyze development of targeted interventions to decrease early readmission, improve patient outcomes, and control health care costs.
PURPOSE: To analyze rate, risk factors, and costs associated with 30-day readmission after ovarian cancer surgery. PATIENTS AND METHODS: The SEER-Medicare linked database (1992 to 2010) was used to evaluate readmission rates within 30 days of index surgery in patients with stage IIIC/IV ovarian, primary peritoneal, or fallopian tube cancer. Multivariable logistic regression was used to identify factors associated with readmission. RESULTS: Of 5,152 eligible patients, 1,003 (19.5%) were readmitted within 30 days of discharge. Mean patient age was 75 years. Diagnoses associated with readmission included infection (34.7%), dehydration (34.3%), ileus/obstruction (26.2%), metabolic/electrolyte derangements (23.1%), and anemia (12.3%). In multivariable analysis, year of discharge was significantly associated with 30-day readmission (1996 to 2000: odds ratio [OR], 1.32; 95% CI, 1.01 to 1.71; 2001 to 2005: OR, 1.58; 95% CI, 1.24 to 2.0; 2006 to 2010: OR, 1.73; 95% CI, 1.35 to 2.21; referent years 1992 to 1995), as were length of index hospital stay more than 8 days (OR, 1.39; 95% CI, 1.18 to 1.64) and discharge to a skilled nursing facility (OR, 1.3; 95% CI, 1.04 to 1.63). Patients readmitted within 30 days had a significantly greater 1-year mortality rate compared with patients not readmitted (41.1% v 25.1%, respectively; P < .001). The median cost of readmission hospital stay was $9,220 in year 2010 dollars, with a total cost of $9.3 million over the study period. CONCLUSION: Early readmission after surgery for ovarian cancer is common. There is a significant association between 30-day readmission and 1-year mortality. These findings may catalyze development of targeted interventions to decrease early readmission, improve patient outcomes, and control health care costs.
Authors: Edward L Hannan; Ye Zhong; Harlan Krumholz; Gary Walford; David R Holmes; Nicholas J Stamato; Alice K Jacobs; Ferdinand J Venditti; Samin Sharma; Spencer B King Journal: JACC Cardiovasc Interv Date: 2011-12 Impact factor: 11.195
Authors: Elizabeth C Wick; Andrew D Shore; Kenzo Hirose; Andrew M Ibrahim; Susan L Gearhart; Jonathan Efron; Jonathan P Weiner; Martin A Makary Journal: Dis Colon Rectum Date: 2011-12 Impact factor: 4.585
Authors: Jason H Wasfy; Kenneth Rosenfield; Katya Zelevinsky; Rahul Sakhuja; Ann Lovett; John A Spertus; Neil J Wimmer; Laura Mauri; Sharon-Lise T Normand; Robert W Yeh Journal: Circ Cardiovasc Qual Outcomes Date: 2013-07-02
Authors: Marlow B Hernandez; Randall S Schwartz; Craig R Asher; Elsy V Navas; Victor Totfalusi; Ivan Buitrago; Ankush Lahoti; Gian M Novaro Journal: Clin Cardiol Date: 2013-08-08 Impact factor: 2.882
Authors: Caroline J Rieser; Jurgis Alvikas; Heather Phelos; Lauren B Hall; Amer H Zureikat; Andrew Lee; Melanie Ongchin; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry Journal: Ann Surg Oncol Date: 2022-01-06 Impact factor: 5.344
Authors: Michael D Toboni; Haller J Smith; Sejong Bae; J Michael Straughn; Charles A Leath Journal: Int J Gynecol Cancer Date: 2018-09 Impact factor: 3.437
Authors: Jacob K Greenberg; Ridhima Guniganti; Eric J Arias; Kshitij Desai; Chad W Washington; Yan Yan; Hua Weng; Chengjie Xiong; Emily Fondahn; DeWitte T Cross; Christopher J Moran; Keith M Rich; Michael R Chicoine; Rajat Dhar; Ralph G Dacey; Colin P Derdeyn; Gregory J Zipfel Journal: J Neurosurg Date: 2016-08-05 Impact factor: 5.115
Authors: Ian A Buchanan; Michelle Lin; Daniel A Donoho; Li Ding; Steven L Giannotta; Frank Attenello; William J Mack; John C Liu Journal: World Neurosurg Date: 2019-01-23 Impact factor: 2.104
Authors: Kamila Hoenk; Lilibeth Torno; William Feaster; Sharief Taraman; Anthony Chang; Michael Weiss; Karen Pugh; Brittney Anderson; Louis Ehwerhemuepha Journal: Cancer Rep (Hoboken) Date: 2021-02-02